Biopharmaceutical Report II Issue25_December 2021 As Merck (NYSE:MRK) and Ridgeback Biotherapeutics sign on to a licensing deal to expand...

Biopharmaceutical Report I Issue25_December 2021 Value-based plans are emerging as particularly attractive coverage options for therapies...

Biopharmaceutical Report II Issue24_September 2021 By opening a National Coverage Determination (NCD) on Biogen’s (NASDAQ:BIIB) Aduhelm...

Biopharmaceutical Report I Issue24_September 2021 Blood cancer oncologists are likely to hold back for now on using Oncopeptides’...

Steve Usdin, Washington Editor Biopharmaceutical Report III Issue22_March 2021 The fight against COVID-19 is far from finished, but...

Biopharmaceutical Report II Issue23_March 2021 COVID-19 long-hauler treatment trials will likely rely on established endpoints and trial...

Biopharmaceutical Report I Issue23_March 2021 Long-term COVID-19 vaccine durability has become less of an endgame since it has become...

Biopharmaceutical Report IV Issue22_November 2020 COVID-19 didn’t disappear with summer temperatures, it just shifted locations and...

Biopharmaceutical Report III Issue22_November 2020 Treatments for COVID-19 may be focusing on at the wrong elements of the disease,...

Biopharmaceutical Report II Issue22_November 2020 Fate Therapeutics’ (NASDAQ:FATE) and Celyad’s (NASDAQ:CYAD) natural killer (NK) cell...